Solvato-polymorph of [(η6-C6H6)RuCl (L)]PF6 (L = (2,6-dimethyl-phenyl-pyridin-2-yl methylene amine)

Chlorido-{2-[(4-chloro-phen-yl)imino-meth-yl]pyridine-κ2 N,N'}(η6-toluene)-ruthenium(II) hexa-fluoridophosphate

The asymmetric unit of the title compound, [RuCl(C7H8)(C12H9ClN2)]PF6, contains two cationic ruthenium(II) complexes and two [PF6]- anions. One of the anions exhibits disorder over two positions. The ruthenium complex adopts a piano-stool geometry, with chelating Schiff base and chlorido ligands occupying three coordination sites, and the arene ring serving as the 'seat'.

Mononuclear η6-arene ruthenium(II) complexes with pyrazolyl-pyridazine ligands: synthesis, CT-DNA binding, reactivity towards glutathione, and cytotoxicity

Organometallic η6-arene ruthenium(II) complexes with 3-chloro-6-(1H-pyrazol-1-yl)pyridazine (Ru1, Ru2, and Ru5) and 3-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridazine (Ru3-4) N,N' heterocyclic and η6-arene (cymene (Ru1-4) or toluene (Ru 5)) have been synthesized. The ruthenium(II) complexes have common "three-legged piano-stool" pseudo-octahedral structures known for half-sandwich complexes. Evolution of their UV-Visible absorption spectra in PBS buffer or DMSO over 24 h confirmed their good solvolysis stability. Titrations of the complexes with the calf thymus DNA (CT-DNA) were monitored using UV-Visible absorption and fluorescence spectroscopies. The complexes interact moderately with CT-DNA and their binding constants are in the order of 104 M-1. Competitive binding of the complexes to a DNA-Hoechst 33,258 depicted competitive displacement of Hoechst from DNA's minor grooves. These complexes bind to glutathione forming GSH-adducts through S coordination by replacement of a halide, with the iodo-analogues having higher binding constants than the chloro-complexes. Cyclic voltammograms of the complexes exhibited one electron-transfer quasi-reversible process. Trends in the molecular docking data of Ru1-5/DNA were similar to those for DNA binding constants. Of the five, only Ru1, Ru3 and Ru5 showed some activity (moderate) against the MCF-7 breast cancer cells with IC50 values in the range of 59.2-39.9 for which Ru5 was the most active. However, the more difficult-to-treat cell line, MDA-MB 231 cell was recalcitrant to the treatment by these complexes.

Crystal Structures of Half-Sandwich Ru(II) Complexes, [(η6-p-Cymene)(3-chloro-6-(1H-pyrazol-1-yl)pyridazine)Ru(X)]BF4, (X = Cl, Br, I)

Herein, we report the synthesis and single-crystal X-ray structures of three (η6-p-cymene)Ru(II) tetrafluoroborate salts, viz., [(η6-p-cymene)(3-chloro-6-(1H-pyrazol-1-yl)pyridazine)Ru(X)]BF4, (X = Cl, Br, I), Ru1-3. They were prepared by the reactions of [(η6-p-cymene)Ru(μ-X)(X)]2, (X = Cl, Br, I) with two-mole equivalents of 3-chloro-6-(1H-pyrazol-1-yl)pyridazine, under inert conditions at ambient temperatures, and subsequently precipitated by the addition of excess BF4− ions. Orange crystalline precipitates were obtained in good yields, from which the respective single crystals for X-ray diffraction analysis were recrystallized by slow evaporation from their methanolic/diethyl ether solutions. The Ru(II) complexes were characterized by various spectroscopic techniques and chemical methods, which included FTIR, 1H/13C NMR, UV-visible absorption, mass spectrometry, and elemental analysis. The molecular structures were solved by single-crystal X-ray crystal diffraction analysis. The complexes crystallized in the monoclinic crystal system in the P21/c (Ru1-2) and P21/n (Ru3) space groups. Density Functionals Theoretical (DFT) calculations were performed in methanol to gain an understanding of the electronic and structural properties of the complexes. Trends in the data metrics were established, and selected data were compared with the diffraction data. The electrophilicity indices of Ru1-3 follow the order Ru3 > Ru2 > Ru1, and the trend is in line with their anticipated order of reactivity towards nucleophiles.

Crystal structure of chlorido-(η 6-toluene)(5,5′-dimethyl-2,2′-bipyridine-κ2 N,N′)ruthenium(II) hexafluoridophosphate(V) ─ acetone (1/1) C22H26ClN2ORuPF6

C22H26ClN2ORuPF6, triclinic, P 1 ‾ $\overline{1}$ (no. 2), a = 10.2106(4) Å, b = 10.8139(4) Å, c = 11.1963(4) Å, α = 93.765(2)°, β = 90.418(1)°, γ = 94.324(2)°, V = 1229.98(8) Å3, Z = 2, R gt (F) = 0.0251, wR ref (F 2) = 0.0683, T = 100 K.

Crystal structure of chlorido-(η 6-toluene)(2,2′-bipyridine-κ2 N,N′)ruthenium(II) hexafluorophosphate, C17H16ClN2RuPF6

C17H16ClN2RuPF6, monoclinic, P21/c (no. 14), a = 14.4426(9) Å, b = 8.3311(5) Å, c = 16.413(1) Å, β = 109.2690°, V = 1864.2(2) Å3, Z = 4, R gt (F) = 0.0309, wR ref (F 2) = 0.0697, T = 173 K.

Mifepristone polymorph with enhanced solubility, dissolution and oral bioavailability

Mifepristone is one of potent anti-progesterone agents, which binds to progesterone receptors and glucocorticoid receptors. Until now, there are a lot of research focusing on enhancing the solubility and oral bioavailability of Mifepristone. However, poor solubility and oral bioavailability has some undesirable consequences. In this work, Mifepristone in form D was discovered for the first time and characterized by PXRD, TGA, DSC, FT-IR, SEM and SS NMR. Form D was a metastable crystal type which manifested favorable stability under ambient conditions. Form D had better dissolution characteristic compared with commercial Mifepristone in 0.5% SDS solution. In addition, Mifepristone in form D exhibited a 1.43-fold higher peak plasma concentration (C_max) and 1.46-fold higher area under the curve (AUC) in rats. The work in this paper is a complement to the present understanding of drug polymorphism on the in vitro and in vivo behavior, and establishes the ground work for future development of Mifepristone in form D as a promising drug for the market.

Synthesis, characterization, anticancer and antimicrobial study of arene ruthenium(II) complexes with 1,2,4-triazole ligands containing an α-diimine moiety

The reaction of the ruthenium arene dimers [(η 6-arene)Ru(μ-Cl)Cl]2 (where arene=benzene or p-cymene) with the ligands 4-benzylidene-3,5-di(2′-pyridyl)-4-amino-1,2,4-triazole (L1 ), 2-methoxybenzylidene-3,5-di(2′-pyridyl)-4-amino-1,2,4-triazole (L2 ), 4-methylbenzylidene-3,5-di(2′-pyridyl)-4-amino-1,2,4-triazole (L3 ) and indole-3-carbaldehyde-3,5-di(2′-pyridyl)-4-amino-1,2,4-triazole (L4 ) in a 1:2 ratio gives the new complexes [(η 6-arene)RuCl(L)]+ [arene=C6H6 (with L=L1(1), L2(3), L4(7), with PF6 − as a counter ion, and L4 (6), with Cl− as a counter ion) or p-cymene with L=L1(2), L2(4), L3(5), L4(8) with PF6 − as a counter ion]. All complexes were fully characterized using 1H and 13C NMR, elemental analyses, UV/Vis and IR spectroscopy. The single crystal X-ray structures of ligand L2 and complex 1 have been determined. The structure of 1 has the Ru atom coordinated with the arene group and to the N,N′-bidentate ligand and to the Cl atom. The arene group occupies the apex, while the ligand and the Cl atom are at the base of a pseudo-octahedral three-legged piano stool. The cytotoxicity of these mononuclear complexes was established in the human epithelial colorectal adenocarcinoma cell line (Caco-2) and for selectivity in the non-cancerous human embryonic kidney cell line (HEK293), using 5-fluorouracil (5-FU) as the reference anticancer drug. Compounds 1 and 7 were relatively inactive toward the Caco-2 tumor cells (IC50>200), while complexes 2–5 showed moderate anti-proliferative properties (IC50>100–200). Compound 6, however, displayed better anti-proliferative properties with an IC50 value lower than that of the reference drug, 5-FU, and was therefore further investigated for its antimicrobial activity against six Gram-positive and four Gram-negative bacteria.

Crystal structure of (η 6-benzene)-(N-(2,6-dimethylphenyl)-1-(pyridin-2-yl)methanimine-κ2 N,N′)ruthenium(II) perchlorate monohydrate, C20H20Cl2N2O5Ru

C20H20Cl2N2O5Ru, monoclinic, P1̅ (no. 2), a = 8.7921(2) Å, b = 11.2515(3) Å, c = 11.7014(3) Å, α = 103.752(1)°, β = 107.296(1)°, γ = 98.562(1)°, V = 1043.01(5) Å3, Z = 2, R gt(F) = 0.0198, wR ref(F 2) = 0.0553, T = 173 K.

Crystal structure of chlorido-(N-(2,5-dichlorophenyl)-1-(pyridin-2-yl)methanimine-κ2 N,N′)(η 6-1-isopropyl-4-methyl benzene) ruthenium (II) tetrafluoroborate, C22H22Cl3N2BF4Ru

C22H22Cl3N2BF4Ru, monoclinic, P21/n (no. 14), a = 15.067(5) Å, b = 10.409(5) Å, c = 16.503(5) Å, β = 112.75(5)°, V = 2386.9(16) Å3, Z = 4, R gt(F) = 0.0211, wR ref(F 2) = 0.0535, T = 173 K.

Crystal structure of chlorido-(η6–1-isopropyl-4-methyl benzene)-(1-(pyridin-2-yl)-N-(p-tolyl)methanimine-κ2 N,N′)ruthenium(II) hexafluorophosphate(V), C23H26ClF6N2PRu

C23H26ClF6N2PRu, triclinic, P1̅ (no. 2), a = 8.9950(6) Å, b = 11.1669(8) Å, c = 12.4128(9) Å, α = 80.520(2)°, β = 87.5360(10)°, γ = 86.3200(10)°, V = 1226.59(15) Å3, Z = 2, R gt(F) = 0.0267, wR ref(F 2) = 0.0622, T = 173(2) K.